Barbara Jóźwiak

Barbara Jóźwiak

Auto-generated profile, based on publicly available information

Barbara Jóźwiak

Department of Rheumatology, Systemic Connective Tissue Diseases and Immunotherapy of Rheumatic Diseases, J. Strus Municipal Hospital, 61-285 Poznan, Poland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2022 in Annals of Agricultural and Environmental Medicine
Verified
Journal Article
Open access
WSWiktor Schmidt
Wiktor Schmidt
BJBarbara Jóźwiak
Barbara Jóźwiak
ZCZofia Czabajska
Zofia Czabajska
KPKatarzyna Pawlak-Buś
Katarzyna Pawlak-Buś
PLPiotr Leszczynski
Piotr Leszczynski
Introduction and objective: Recognition of patients with COVID-19 who will progress clinically and need respiratory support remains challenging. The aim of the study was to identify abnormalities in on-admission laboratory results that can precede progression from moderate or severe to critical...

22 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
WSWiktor Schmidt
Wiktor Schmidt
KPKatarzyna Pawlak-Buś
Katarzyna Pawlak-Buś
BJBarbara Jóźwiak
Barbara Jóźwiak
PLPiotr Leszczyński
Piotr Leszczyński
Hyperinflammation in COVID-19 plays a crucial role in pathogenesis and severity; thus, many immunomodulatory agents are applied in its treatment. We aimed to identify good clinical response predictors of tocilizumab (TCZ) treatment in severe COVID-19, among clinical, laboratory, and radiological variables. We conducted a prospective, observational study with 120 patients with severe COVID-19 not improving despite dexamethasone (DEX) treatment. We used parametric and non-parametric statistics, univariate logistic regression, receiver operating characteristic (ROC) curves, and nonlinear factors tertile analysis. In total, 86 (71.7%) patients achieved the primary outcome of a good clinical response to TCZ. We identified forty-nine predictive factors with potential utility in patient selection and treatment monitoring. The strongest included time from symptom onset between 9 and 12 days, less than 70% of estimated radiological lung involvement, and lower activity of lactate dehydrogenase. Additional predictors were associated with respiratory function, vitamin D concentration, comorbidities, and inflammatory/organ damage biomarkers. Adverse events analysis proved the safety of such a regimen. Our study confirmed that using TCZ early in the hyperinflammatory phase, before severe respiratory failure development, is most beneficial. Considering the described predictive factors, employing simple and widely available laboratory, radiological, and clinical tools can optimize patient selection for immunomodulatory treatment with TCZ.